Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 1065-1075

  Insull Jr , William ^a   Toth, Peter P ^b   Superko, H Robert ^c   Thakkar, Roopal B ^d   Krause, Scott ^d   Jiang, Ping ^d   Parreno, Rhea A ^d   Padley, Robert J ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c MERCER UNIVERSITY   (United States)

^d ABBOTT LABORATORIES   (United States)

Author keywords

Atorvastatin; Diameter; Dyslipidemia; Lipid particles; Niacin; Number; Simvastatin; Size

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHYLOMICRON; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID PLUS SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATHEROGENESIS; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; FLUSHING; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NIACIN; PYRROLES; SIMVASTATIN; TREATMENT OUTCOME; UNITED STATES;

EID: 80051882497     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S14053     Document Type: Article

References (63)

1. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
2. Krauss RM. Is the size of low-density lipoprotein particles related to the risk of coronary heart disease? JAMA. 2002;287:712-713.
3. Gazi IF, Tsimihodimos V, Tselepis AD, Elisaf M, Mikhailidis DP. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther. 2007;7:53-72.
4. El-Harchaoui K, van der Steeg WA, Stroes ES, et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: The EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;49: 547-553.
5. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31:811-822.
6. de Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease and prevention in clinical practice. Atherosclerosis. 2003;171:145-155.
7. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Eur Heart J. 2007;28:2375-2414.
8. Krauss RM, Blanche PJ. Detection and quantitation of LDL-C subfrac-tions. Curr Opin Lipidol. 1992;3:377-383.
9. Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol. 1994;5:339-349.
10. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfbrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation. 2006;113:1556-1563.
11. Arsenault BJ, Lemieux I, Despres JP, et al. HDL particle size and the risk of coronary heart disease in apparently healthy men and women: The EPIC-Norfolk prospective population study. Atherosclerosis. 2009;206:276-281.
12. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res. 1982;23:97-104.
13. Superko HR. The atherogenic lipoprotein profle. Sci Med. 1997;4: 36-45.
14. van der Steeg WA, Holme I, Boekholdt SM, et al. High-density lipo-protein cholesterol, high-density lipoprotein particle size, and apoli-poprotein A-I: Significance for cardiovascular risk: The IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol. 2008;51:634-642.
15. Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk: Position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem. 2009;55:407-419.
16. Superko HR. Advanced lipoprotein testing and subfractionation are clinically useful. Circulation. 2009;119:2383-2395.
17. The Coronary Drug Project. Design, methods, and baseline results. Circulation. 1973;47(3 Suppl 1):I1-I50.
18. ® [Package insert]. North Chicago, IL: Abbott Laboratories; 2005.
19. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: Long-term beneft with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
20. Ganji SH, Kamanna VS, Kashyap ML. Niacin and cholesterol: Role in cardiovascular disease. J Nutr Biochem. 2003;14:298-305.
21. Guyton JR. Niacin in cardiovascular prevention: Mechanisms, efficacy, and safety. Curr Opin Lipidol. 2007;18:415-420.
22. Kuvin JT, Dave DM, Sliney KA, et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol. 2006; 98:743-745.
23. Superko HR, McGovern ME, Raul E, Garrett B. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I. Am J Cardiol. 2004;94:588-594.
24. Assmann G. Beyond statin therapy: Why we need new thinking. Curr Med Res Opin. 2005;21 Suppl 6:S3-S8.
25. Robinson JG. Simvastatin: Present and future perspectives. Expert Opin Pharmacother. 2007;8:2159-2227.
26. Violi F, Micheletta F, Iuliano L. MRC/BHF Heart Protection Study. Lancet. 2002;360:1782-1783.
27. Chan SY, Mancini GB, Ignaszewski A, Frohlich J. Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: A randomized crossover study. BMC Clin Pharmacol. 2008;8:10.
28. Karalis DG, Ishisaka DY, Luo D, Ntanios F, Wun CC. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia. Am J Cardiol. 2007;100:445-449.
29. Superko HR, Krauss RM, DiRicco C. Effect of fuvastatin on low-density lipoprotein peak particle diameter. Am J Cardiol. 1997;80:78-81.
30. Insull WBJ Jr, Vo AN, Jiang P, Thakkar R, Padley RJ. Efficacy and safety of combination therapy with niacin extended-release and simvas-tatin versus atorvastatin in patients with dyslipidemia: The SUPREME Study. J Clin Lipidol. 2009;3:109-118.
31. Freedman DS, Otvos JD, Jeyarajah EJ, et al. Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: The Framingham Study. Clin Chem. 2004;50: 1189-1200.
32. Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab. 2002;48: 171-180.
33. Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem. 1992;38:1632-1638.
34. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: Consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51:1512-1524.
35. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26: 847-870.
36. Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 2002;106:1930-1937.
37. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipo-protein particle profles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009;119:931-939.
38. Sniderman AD, Silberberg J. Is it time to measure apolipoprotein B? Arteriosclerosis. 1990;10:665-667.
39. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet. 2001;358:2026-2033.
40. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998;97:1453-1460.
41. Sniderman A, Vu H, Cianfone K. Effect of moderate hypertriglyc-eridemia on the relation of plasma total and LDL-C apo B levels. Atherosclerosis. 1991;89:109-116.
42. Kastelein JJ, van der Steeg WA, Holme I, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117:3002-3009.
43. Li TY, Brennan AM, Wedick NM, Mantzoros C, Rifai N, Hu FB. Regular consumption of nuts is associated with a lower risk of cardiovascular disease in women with type 2 diabetes. J Nutr. 2009;139: 1333-1338.
44. Simes RJ, Marschner IC, Hunt D, et al. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: To what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation. 2002;105:1162-1169.
45. Mora SOJ, Buring JE, Rifai N, Ridker PM. A prospective comparison of NMR-measured LDL-C particle number, apolipoprotein B100, and standard lipids with incident CHD in 27,673 initially healthy women. Circulation. 2007;116:3481.
46. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294:326-333.
47. Cromwell WC, Otvos JD, Keyes MJ, et al. LDL-C particle number and risk of future cardiovascular disease in the Framingham offspring study - implications for LDL-C management. J Clin Lipidol. 2007;1:583-592.
48. Sniderman AD, Bergeron J, Frohlich J. Apolipoprotein B versus lipo-protein lipids: Vital lessons from the AFCAPS/TexCAPS trial. CMAJ. 2001;164:44-47.
49. Morgan JM, Capuzzi DM, Baksh RI, et al. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol. 2003;91: 1432-1436.
50. Jafri H, Alsheikh AA, Mooney P, Kimmelstiel CD, Karas RH, Kuvin JT. Extended-release niacin reduces LDL-C particle number without changing total LDL-C cholesterol in patients with stable CAD. J Clin Lipidol. 2009;3:45-50.
51. Skoglund-Andersson C, Tang R, Bond MG, de Faire U, Hamsten A, Karpe F. LDL-C particle size distribution is associated with carotid intima-media thickness in healthy 50-year-old men. Arterioscler Thromb Vasc Biol. 1999;19:2422-2430.
52. Williams PT, Superko HR, Haskell WL, et al. Smallest LDL-C particles are most strongly related to coronary disease progression in men. Arte-rioscler Thromb Vasc Biol. 2003;23:314-321.
53. Insull W Jr. The pathology of atherosclerosis: Plaque development and plaque responses to medical treatment. Am J Med. 2009;122:S3-S14.
54. Norata GD, Raselli S, Grigore L, et al. Small dense LDL-C and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells. Atherosclerosis. 2009;206:556-562.
55. de Groot E, Jukema JW, Montauban van Swijndregt AD, et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic fndings: A report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol. 1998;31:1561-1567.
56. Furberg CD, Adams HP Jr, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation. 1994;90:1679-1687.
57. MacMahon S, Sharpe N, Gamble G, et al. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: Results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation. 1998;97:1784-1790.
58. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin. 2006;22:2243-2250.
59. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512-3517.
60. Lee JM, Robson MD, Yu LM, et al. Effects of high-dose modifed-release nicotinic acid on atherosclerosis and vascular function: A randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol. 2009;54:1787-1794.
61. Airan-Javia SL, Wolf RL, Wolfe ML, Tadesse M, Mohler E, Reilly MP. Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy. Am Heart J. 2009;157:687.e1-e8.
62. Karas RH, Kashyap ML, Knopp RH, Keller LH, Bajorunas DR, Davidson MH. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: The OCEANS study. Am J Cardiovasc Drugs. 2008;8:69-81.
63. Karas RH DM, Kashyap ML, Thakkar RB, Jiang P, Padely RJ. Addition of niacin extended-release to baseline statin treatment reduces hsCRP in patients with mixed dyslipidemia and elevated hsCRP. XV International Symposium on Atherosclerosis 2009. Boston, MA. 2009 Jun 17.